Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Terence J. Hadley"'
Autor:
Stacy S. Epstein, Terence J. Hadley
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 44:815-818
What is known and objective Hyperhaemolysis syndrome (HHS) of sickle cell anaemia (SCA) is a life-threatening condition characterized by accelerated destruction of red blood cells typically following blood transfusions. Optimal treatment strategies h
Autor:
Howard A. Burris, David R. Spigel, F. Anthony Greco, Tarek Mekhail, Terence J. Hadley, Charles D. Webb, John D. Hainsworth, David M. Waterhouse
Publikováno v:
Cancer investigation. 35(8)
Background: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. Methods: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m2 IV, and carboplatin AUC = 6 I
Autor:
Terence J. Hadley, M. Marasa, George H. Goldsmith, Geetha Joseph, A. Huang, D. Vaughn, Benjamin Djulbegovic, J. Birkimer
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 2(3)
Summary. In a prospective study, we tested the hypothesis that an already reduced quality of life in haemophilia patients is further diminished in those haemophilia patients who contracted the human immunodeficiency virus (HIV) as a result of transfu
Autor:
Doug Lorenz, Lynne M. Roetzer, Terence J. Hadley, Kelly M. McMasters, Troy D. Abell, Sean P. Dineen, Ahmed YoussefAgha, Jamie L. Studts, Celia Chao
Publikováno v:
Journal of Clinical Oncology. 21:4299-4305
Purpose: The purpose of this study was to examine the impact of four methods of communicating survival benefits on chemotherapy decisions. We hypothesized that the four methods of communicating mathematically equivalent risk information would lead to
Autor:
Terence J. Hadley, Stephen C. Peiper
Publikováno v:
Blood. 89:3077-3091
ONE OF THE MOST notable achievements of biomedical research in the first half of this century was the identification of red blood cell (RBC) antigens and the recognition of their importance to transfusion medicine and hemolytic disease of the newborn
Autor:
Dominique Blanchard, Terence J. Hadley, Stephen C. Peiper, Zi-Xuan Wang, Kazimiera Waśniowska, Daniel Janvier, Elwira Lisowska
Publikováno v:
Molecular Immunology. 33:917-923
The epitope Fy6 recognized by two monoclonal antibodies (i3A and BG6), which inhibit binding of chemokines to the Duffy antigen, was characterized by means of peptides synthesized on pins (Epitope Scanning Kit) and deletion mutagenesis. Both antibodi
Autor:
Terence J. Hadley, A. W. Martin, R. Horuk, J. Hesselgesser, Zhao-Hai Lu, Stephen C. Peiper, Zi-Xuan Wang
Publikováno v:
Journal of Leukocyte Biology. 59:29-38
The Duffy antigen receptor for chemokines (DARC) is expressed in human erythrocytes and on endothelial cells lining postcapillary venules in kidney and spleen. DARC is a promiscuous chemokine receptor and a binding protein for the malarial parasite P
Autor:
Thomas M. Woodcock, Terence J. Hadley, F.J. Hendler, Janell Seeger, Geetha Joseph, Morris K, John T. Hamm, Martin S. Blumenreich
Publikováno v:
American Journal of Clinical Oncology. 18:385-388
A total of 35 women with advanced, metastatic breast cancer were treated with combination chemotherapy consisting of folinic acid 500 mg/m 2 over 2 hours administered with 600 mg/m 2 of 5FU at the midpoint of the folinic acid infusion weekly for 6 we
Autor:
K. Neote, Terence J. Hadley, J. Hesselgesser, Richard Horuk, Stephen C. Peiper, M. J. Conklyn, Zhao-Hai Lu, K. Ogborne, Zi-Xuan Wang, H. J. Showell, A. W. Martin
Publikováno v:
The Journal of Experimental Medicine
The Duffy antigen/receptor for chemokines (DARC), first identified on erythrocytes, functions not only as a promiscuous chemokine receptor but also as a receptor for the malarial parasite, Plasmodium vivax. The recent finding that DARC is ubiquitousl
Autor:
Terence J. Hadley, Gary M. Troup, Kenneth J. Smith, Geetha Joseph, John W. Oldfather, Robert L. Barker, Benjamin Djulbegovic
Publikováno v:
American Journal of Hematology. 47:189-193
Class I and Class II HLA antigens were tested in patients treated for thrombotic thrombocytopenic purpura or hemolytic uremic syndrome (TTP/HUS) to determine whether there is a disease association. Based on the results of a pilot trial, retrospective